EZZ Life Science Holdings Limited
EZZ Life Science Holdings Limited Fundamental Analysis
EZZ Life Science Holdings Limited (EZZ.AX) shows moderate financial fundamentals with a PE ratio of 13.18, profit margin of 4.71%, and ROE of 10.35%. The company generates $0.1B in annual revenue with strong year-over-year growth of 78.88%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 63.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze EZZ.AX's fundamental strength across five key dimensions:
Efficiency Score
WeakEZZ.AX struggles to generate sufficient returns from assets.
Valuation Score
ExcellentEZZ.AX trades at attractive valuation levels.
Growth Score
ExcellentEZZ.AX delivers strong and consistent growth momentum.
Financial Health Score
ExcellentEZZ.AX maintains a strong and stable balance sheet.
Profitability Score
WeakEZZ.AX struggles to sustain strong margins.
Key Financial Metrics
Is EZZ.AX Expensive or Cheap?
P/E Ratio
EZZ.AX trades at 13.18 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, EZZ.AX's PEG of -0.22 indicates potential undervaluation.
Price to Book
The market values EZZ Life Science Holdings Limited at 1.37 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 9.50 times EBITDA. This is generally considered low.
How Well Does EZZ.AX Make Money?
Net Profit Margin
For every $100 in sales, EZZ Life Science Holdings Limited keeps $4.71 as profit after all expenses.
Operating Margin
Core operations generate 12.95 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $10.35 in profit for every $100 of shareholder equity.
ROA
EZZ Life Science Holdings Limited generates $8.87 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
EZZ Life Science Holdings Limited generates limited operating cash flow of $-2.62M, signaling weaker underlying cash strength.
Free Cash Flow
EZZ Life Science Holdings Limited generates weak or negative free cash flow of $-2.69M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.06 in free cash annually.
FCF Yield
EZZ.AX converts -7.06% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
13.18
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.22
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.37
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.62
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.004
vs 25 benchmark
Current Ratio
Current assets to current liabilities
6.57
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.29
vs 25 benchmark
How EZZ.AX Stacks Against Its Sector Peers
| Metric | EZZ.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 13.18 | 28.45 | Better (Cheaper) |
| ROE | 10.35% | 763.00% | Weak |
| Net Margin | 4.71% | -45265.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 6.57 | 2795.60 | Strong Liquidity |
| ROA | 8.87% | -16588.00% (disorted) | Weak |
EZZ.AX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews EZZ Life Science Holdings Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
478.98%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
724.15%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
1338.62%
Industry Style: Defensive, Growth, Innovation
High Growth